Cargando…

HER2 mRNA Levels, Estrogen Receptor Activity and Susceptibility to Trastuzumab in Primary Breast Cancer

SIMPLE SUMMARY: HER2 mRNA expression is emerging as a powerful predictive biomarker of anti-HER2 drug activity in the treatment of HER2-positive breast cancer patients. Here, we found a positive association between HER2 mRNA levels and disease-free survival in patients treated with adjuvant trastuzu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Triulzi, Tiziana, Regondi, Viola, Venturelli, Elisabetta, Gasparini, Patrizia, Ghirelli, Cristina, Groppelli, Jessica, Di Modica, Martina, Bianchi, Francesca, De Cecco, Loris, Sfondrini, Lucia, Tagliabue, Elda
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688101/ https://www.ncbi.nlm.nih.gov/pubmed/36428742 http://dx.doi.org/10.3390/cancers14225650

Ejemplares similares

HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy
por: Triulzi, Tiziana, et al.
Publicado: (2018)

Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit
por: Triulzi, Tiziana, et al.
Publicado: (2018)

Extracellular Matrix Features Discriminate Aggressive HER2-Positive Breast Cancer Patients Who Benefit from Trastuzumab Treatment
por: Rybinska, Ilona, et al.
Publicado: (2020)

Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition
por: Di Modica, Martina, et al.
Publicado: (2015)

The Link Between the Microbiota and HER2+ Breast Cancer: The New Challenge of Precision Medicine
por: Di Modica, Martina, et al.
Publicado: (2022)

Predicting the Efficacy of HER2-Targeted Therapies: A Look at the Host
por: Di Modica, Martina, et al.
Publicado: (2017)

Wound Healing Fluid Reflects the Inflammatory Nature and Aggressiveness of Breast Tumors
por: Agresti, Roberto, et al.
Publicado: (2019)

Infrared Spectroscopic Imaging Visualizes a Prognostic Extracellular Matrix-Related Signature in Breast Cancer
por: Tiwari, Saumya, et al.
Publicado: (2020)

Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration
por: Triulzi, Tiziana, et al.
Publicado: (2015)

Local Administration of Caloric Restriction Mimetics to Promote the Immune Control of Lung Metastases
por: Le Noci, Valentino, et al.
Publicado: (2019)

The Emerging Role of the Microbiota in Breast Cancer Progression
por: Bernardo, Giancarla, et al.
Publicado: (2023)

Expression Profile of Tyrosine Phosphatases in HER2 Breast Cancer Cells and Tumors
por: Lucci, Maria Antonietta, et al.
Publicado: (2010)

The Educational Program of Macrophages toward a Hyperprogressive Disease-Related Phenotype Is Orchestrated by Tumor-Derived Extracellular Vesicles
por: Indino, Serena, et al.
Publicado: (2022)

The PDGFRβ/ERK1/2 pathway regulates CDCP1 expression in triple-negative breast cancer
por: Forte, Luca, et al.
Publicado: (2018)

CDCP1 is a novel marker of the most aggressive human triple-negative breast cancers
por: Turdo, Federica, et al.
Publicado: (2016)

Tumor Extracellular Matrix Remodeling: New Perspectives as a Circulating Tool in the Diagnosis and Prognosis of Solid Tumors
por: Giussani, Marta, et al.
Publicado: (2019)

Cancer-Associated Adipocytes in Breast Cancer: Causes and Consequences
por: Rybinska, Ilona, et al.
Publicado: (2021)

Live or Heat-Killed Lactobacillus rhamnosus Aerosolization Decreases Adenomatous Lung Cancer Development in a Mouse Carcinogen-Induced Tumor Model
por: Le Noci, Valentino, et al.
Publicado: (2022)

Exploiting poly(I:C) to induce cancer cell apoptosis
por: Bianchi, Francesca, et al.
Publicado: (2017)

Adipocytes in Breast Cancer, the Thick and the Thin
por: Rybinska, Ilona, et al.
Publicado: (2020)

Modulation of DNA repair genes induced by TLR9 agonists: A strategy to eliminate “altered” cells?
por: Sommariva, Michele, et al.
Publicado: (2012)

The TRAR gene classifier to predict response to neoadjuvant therapy in HER2‐positive and ER‐positive breast cancer patients: an explorative analysis from the NeoSphere trial
por: Triulzi, Tiziana, et al.
Publicado: (2021)

ELISA assay employing epitope-specific monoclonal antibodies to quantify circulating HER2 with potential application in monitoring cancer patients undergoing therapy with trastuzumab
por: Agnolon, Valentina, et al.
Publicado: (2020)

Toll Like Receptors as Sensors of the Tumor Microbial Dysbiosis: Implications in Cancer Progression
por: Le Noci, Valentino, et al.
Publicado: (2021)

Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer
por: Li, Xin, et al.
Publicado: (2018)

What if the future of HER2‐positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study
por: Pizzamiglio, Sara, et al.
Publicado: (2021)

Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy
por: Munzone, Elisabetta, et al.
Publicado: (2006)

“Omics” and Immunologic Approaches to Optimizing Cure Rates in HER2-Positive Breast Carcinomas
por: Tagliabue, Elda, et al.
Publicado: (2014)

The lung microbiota: role in maintaining pulmonary immune homeostasis and its implications in cancer development and therapy
por: Sommariva, Michele, et al.
Publicado: (2020)

The d16HER2 Splice Variant: A Friend or Foe of HER2-Positive Cancers?
por: Castagnoli, Lorenzo, et al.
Publicado: (2019)

Decoding Immune Heterogeneity of Triple Negative Breast Cancer and Its Association with Systemic Inflammation
por: Romero-Cordoba, Sandra, et al.
Publicado: (2019)

Correction: Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy
por: Munzone, Elisabetta, et al.
Publicado: (2006)

Alterations in mRNA profiles of trastuzumab-resistant Her-2-positive breast cancer
por: Zhao, Bin, et al.
Publicado: (2018)

Different mechanisms for resistance to trastuzumab versus lapatinib in HER2- positive breast cancers -- role of estrogen receptor and HER2 reactivation
por: Wang, Yen-Chao, et al.
Publicado: (2011)

mRNA Profiling Reveals Determinants of Trastuzumab Efficiency in HER2-Positive Breast Cancer
por: von der Heyde, Silvia, et al.
Publicado: (2015)

Neoplastic and Stromal Cells Contribute to an Extracellular Matrix Gene Expression Profile Defining a Breast Cancer Subtype Likely to Progress
por: Triulzi, Tiziana, et al.
Publicado: (2013)

MiR-205 as predictive biomarker and adjuvant therapeutic tool in combination with trastuzumab
por: Cataldo, Alessandra, et al.
Publicado: (2018)

Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer
por: Castagnoli, L, et al.
Publicado: (2017)

TLR3 Expression Induces Apoptosis in Human Non-Small-Cell Lung Cancer
por: Bianchi, Francesca, et al.
Publicado: (2020)

Intratumor lactate levels reflect HER2 addiction status in HER2‐positive breast cancer
por: Castagnoli, Lorenzo, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_6f6kdk53fmamu9dak2boe14goh